Cariprazine in schizophrenia

Cariprazine is an antipsychotic medication which received approval from the US Food and Drug Administration for the treatment of schizophrenia in September 2015. Cariprazine is a dopamine D3 and D2 receptor partial agonist, with a preference for the D3 receptor. While clinical trials are mandatory to provide solid data about the efficacy and tolerability of pharmacological treatments, they may not be representative of the entire patient population, which comprises patients often excluded from clinical trials, showing complex clinical presentation and poor response to usual treatments. This Thematic Series thus provides real-world clinical cases that could help to improve the knowledge of actual effectiveness and tolerability of cariprazine in more difficult clinical scenarios.